Hope Rugo· @hoperugo · X·· 22 小时前评分70
正文 · 原文
Binghe Xu presents data from the Healer trial in China evaluating anbenitamab (bispecific HER2ab) with lipo docetaxel vs THP for HER2+ MBC showing marked improvement in PFS and modest increase in heme tox. Lipo doce approved in US. Today Publ in NEJM! #ESMO2026 @OncoAlert
72 浏览 · 4 赞 · 3 转发 · 1 回复
会议摘要
LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgLBA80按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.org帖内回复
- Hope Rugo@hoperugo
Interesting to consider how this fits into the ADC TDXd world.
来源：Hope Rugo · x.com